Show simple item record

dc.contributor.authorBates, J.P.
dc.contributor.authorDerakhshandeh, R.
dc.contributor.authorJones, L.
dc.date.accessioned2019-04-29T19:01:01Z
dc.date.available2019-04-29T19:01:01Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85046629751&doi=10.1186%2fs12885-018-4441-3&partnerID=40&md5=65e43f7d4ef6d4137348f8bd0bd805db
dc.identifier.urihttp://hdl.handle.net/10713/8946
dc.description.abstractTumors develop multiple mechanisms of immune evasion as they progress, with some cancer types being inherently better at 'hiding' than others. With an increased understanding of tumor immune surveillance, immunotherapy has emerged as a promising treatment strategy for breast cancer, despite historically being thought of as an immunologically silent neoplasm. Some types of cancer, such as melanoma, bladder, and renal cell carcinoma, have demonstrated a durable response to immunotherapeutic intervention, however, breast neoplasms have not shown the same efficacy. The causes of breast cancer's immune silence derive from mechanisms that diminish immune recognition and others that promote strong immunosuppression. It is the mechanisms of immune evasion in breast cancers that are poorly defined. Thus, further characterization is critical for the development of better therapies. This brief review will seek to provide insight into the possible causes of weak immunogenicity and immune suppression mediated by breast cancers and highlight current immunotherapies being used to restore immune responses to breast cancer. Copyright 2018 The Author(s).en_US
dc.description.sponsorshipThis research was supported by grants R21CA184469 and R21CA199544 from the National Cancer Institute of the National Institutes of Health to TJW. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.en_US
dc.description.urihttps://dx.doi.org/10.1186/s12885-018-4441-3en_US
dc.language.isoen_USen_US
dc.publisherBioMed Central Ltd.en_US
dc.relation.ispartofBMC Cancer
dc.subjectPD-1en_US
dc.subjectregulatory T cellsen_US
dc.subject.meshCytokinesen_US
dc.subject.meshDendritic Cellsen_US
dc.subject.meshImmunityen_US
dc.subject.meshImmunotherapyen_US
dc.subject.meshLymphocytesen_US
dc.subject.meshMyeloid-Derived Suppressor Cellsen_US
dc.titleMechanisms of immune evasion in breast canceren_US
dc.typeArticleen_US
dc.identifier.doi10.1186/s12885-018-4441-3
dc.identifier.pmid29751789


This item appears in the following Collection(s)

Show simple item record